CA2950744A1 - Utilisation de secoisolariciresinol diglucosides (sdg) et composes associes pour la protection contre le rayonnement et les dommages chimiques - Google Patents

Utilisation de secoisolariciresinol diglucosides (sdg) et composes associes pour la protection contre le rayonnement et les dommages chimiques Download PDF

Info

Publication number
CA2950744A1
CA2950744A1 CA2950744A CA2950744A CA2950744A1 CA 2950744 A1 CA2950744 A1 CA 2950744A1 CA 2950744 A CA2950744 A CA 2950744A CA 2950744 A CA2950744 A CA 2950744A CA 2950744 A1 CA2950744 A1 CA 2950744A1
Authority
CA
Canada
Prior art keywords
sdg
subject
radiation
exposed
bioactive ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2950744A
Other languages
English (en)
Inventor
Melpo Christofidou-Solomidou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2950744A1 publication Critical patent/CA2950744A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne des compositions et des procédés pour la radioprotection et la chimioprévention faisant appel à des méthodes thérapeutiques et prophylactiques d'utilisation de (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, des analogues de ceux-ci, des stéréoisomères de ceux-ci et d'autres molécules associées.
CA2950744A 2014-05-30 2015-06-01 Utilisation de secoisolariciresinol diglucosides (sdg) et composes associes pour la protection contre le rayonnement et les dommages chimiques Abandoned CA2950744A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462005330P 2014-05-30 2014-05-30
US62/005,330 2014-05-30
US201562101296P 2015-01-08 2015-01-08
US62/101,296 2015-01-08
PCT/US2015/033501 WO2015184441A2 (fr) 2014-05-30 2015-06-01 Utilisation de sécoïsolaricirésinol diglucosides (sdg) et composés associés pour la protection contre le rayonnement et les dommages chimiques

Publications (1)

Publication Number Publication Date
CA2950744A1 true CA2950744A1 (fr) 2015-12-03

Family

ID=54700083

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2950744A Abandoned CA2950744A1 (fr) 2014-05-30 2015-06-01 Utilisation de secoisolariciresinol diglucosides (sdg) et composes associes pour la protection contre le rayonnement et les dommages chimiques

Country Status (9)

Country Link
EP (1) EP3148560A4 (fr)
JP (2) JP2017520620A (fr)
KR (1) KR20170010019A (fr)
CN (2) CN107155304A (fr)
AU (2) AU2015266614A1 (fr)
CA (1) CA2950744A1 (fr)
IL (1) IL249219A0 (fr)
MA (1) MA39899A (fr)
WO (1) WO2015184441A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214039A1 (fr) 2016-06-07 2017-12-14 University Of Pennsylvania Compositions et méthodes destinées à protéger les organes contre les lésions d'ischémie/reperfusion associées à une greffe

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3606325B1 (fr) 2017-04-03 2024-09-04 Gusto Global, LLC Conception rationnelle d'agents biothérapeutiques d'origine microbienne
US20210128596A1 (en) * 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
JP2020535178A (ja) * 2017-09-27 2020-12-03 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 放射線誘発心血管障害に対する保護のためのセコイソラリシレシノールジグルコシド（ｓｄｇ）及び関連化合物の使用
WO2020046476A1 (fr) * 2018-08-31 2020-03-05 Innophos, Inc. Antioxydants végétaux
CN116850162A (zh) * 2023-08-08 2023-10-10 南通大学附属医院 肠二醇在制备治疗放射性肠炎药物中的应用
CN121094806B (zh) * 2025-11-07 2026-02-24 深圳鼎智通讯股份有限公司 一种Android SoftPOS可信应用方法以及应用系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486126B1 (en) * 1999-06-30 2002-11-26 University Of Saskatchewan Technologies Incorporated Antioxidant activity in SDG metabolites
EP1414436A1 (fr) * 2000-06-14 2004-05-06 Alla Shapiro Agents radioprotecteurs
CN100365005C (zh) * 2006-03-02 2008-01-30 江南大学 一种从亚麻籽中提取纯化开环异落叶松树脂酚二葡萄糖苷的方法
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2008147563A1 (fr) * 2007-05-25 2008-12-04 The Trustees Of The University Of Pennsylvania Complexe de lignane de graine de lin, procédés d'utilisation et compositions de celui-ci
WO2010017332A2 (fr) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotecteurs ciblant la thrombospondine-1 et cd47
CN101759731B (zh) * 2008-12-25 2011-10-19 中国科学院兰州化学物理研究所 亚麻籽胶和开环异落叶松树脂酚二葡萄糖苷的提取方法
HRP20181663T1 (hr) * 2013-06-10 2018-12-14 The Trustees Of The University Of Pennsylvania Priprema (s,s)-sekoizolaricirezinol diglukozida i (r,r)-sekoizolaricirezinol diglukozida

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214039A1 (fr) 2016-06-07 2017-12-14 University Of Pennsylvania Compositions et méthodes destinées à protéger les organes contre les lésions d'ischémie/reperfusion associées à une greffe
EP3463334A4 (fr) * 2016-06-07 2020-01-22 University Of Pennsylvania Compositions et méthodes destinées à protéger les organes contre les lésions d'ischémie/reperfusion associées à une greffe

Also Published As

Publication number Publication date
IL249219A0 (en) 2017-02-28
WO2015184441A2 (fr) 2015-12-03
EP3148560A4 (fr) 2018-04-25
AU2015266614A1 (en) 2016-12-15
WO2015184441A9 (fr) 2016-01-21
JP2020121987A (ja) 2020-08-13
EP3148560A2 (fr) 2017-04-05
CN112336736A (zh) 2021-02-09
CN107155304A (zh) 2017-09-12
KR20170010019A (ko) 2017-01-25
MA39899A (fr) 2021-05-26
WO2015184441A3 (fr) 2016-03-10
JP2017520620A (ja) 2017-07-27
AU2020270469A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
AU2020270469A1 (en) Use of secoisolariciresinol diglucosides (SDGs) and related compounds for protection against radiation and chemical damage
Liang et al. Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate-and monosodium urate-induced hyperuricemia and gout in mice
Ghasemi-Pirbaluti et al. The effect of menthol on acute experimental colitis in rats
Antkiewicz-Michaluk et al. Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat
Wang et al. C-phycocyanin mitigates cognitive impairment in doxorubicin-induced chemobrain: impact on neuroinflammation, oxidative stress, and brain mitochondrial and synaptic alterations
Mei et al. FA-97, a new synthetic caffeic acid phenethyl ester derivative, ameliorates DSS-induced colitis against oxidative stress by activating Nrf2/HO-1 pathway
Golbabapour et al. Acute toxicity and gastroprotective role of M. pruriens in ethanol‐induced gastric mucosal injuries in rats
Wu et al. Protective effects of Flagellin a N/C against radiation-induced NLR Pyrin domain containing 3 Inflammasome-dependent Pyroptosis in intestinal cells
Djordjevic et al. Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver
Moussa et al. A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease
US10966995B2 (en) Use of secoisolariciresinol diglucosides (SDGS) and related compounds for protection against radiation and chemical damage
JP5620443B2 (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
US8029770B2 (en) Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
JP2025119055A (ja) 癌治療
Aldbass et al. Protective and therapeutic potency of N-acetyl-cysteine on propionic acid-induced biochemical autistic features in rats
Alharthi Chicoric acid enhances the antioxidative defense system and protects against inflammation and apoptosis associated with the colitis model induced by dextran sulfate sodium in rats
Galvani et al. Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases
Pietrofesa et al. The synthetic lignan secoisolariciresinol diglucoside prevents asbestos‐induced NLRP3 inflammasome activation in murine macrophages
WO2015069562A1 (fr) Régime de traitement du cancer par la génistéine rendant maximaux les bienfaits de radiothérapie du cancer
Sun et al. Targeting MCL1 with Sanggenon C overcomes MCL1-driven adaptive chemoresistance via dysregulation of autophagy and endoplasmic reticulum stress in cervical cancer
Wang et al. Effects of mimic of manganese superoxide dismutase on 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis in rats
Cuzzocrea et al. Synergistic interaction between methotrexate and a superoxide dismutase mimetic: pharmacologic and potential clinical significance
US20230310359A1 (en) Anti-Oncogenic Phytochemicals and Methods and Uses for Treating Cancer
HK1240082A1 (en) Use of secoisolariciresinol diglucosides (sdgs) and related compounds for protection against radiation and chemical damage
Sardar et al. Oral delivery of the non-β-blocking R-carvedilol enantiomer for skin cancer chemoprevention in SKH-1 mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200601

FZDE Discontinued

Effective date: 20221028